Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 4Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Mesothelioma 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Ovarian Cancer 1

Interventions

LMB-100 4Cyclophosphamide 3fludarabine 2Plicamycin 2Cisplatin 2talazoparib 1pembrolizumab 1olaparib 1fludarabine phosphate 1decitabine and cedazuridine drug combination 1amatuximab 1alvocidib 1aldesleukin 1Surgical Procedures, Operative 1Pentostatin 1Pemetrexed 1Paclitaxel 1Magnetic Resonance Imaging 1Ipilimumab 1Fluorouracil 1Fluorodeoxyglucose F18 1Famotidine 1FANG vaccine 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Dexamethasone 1Depsipeptides 1Cytoreduction Surgical Procedures 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Mesothelioma × talazoparib × Clear all
NCT02567396 2017-04-24

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

Phase 1 Withdrawn
BreastGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡